The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index; 28 of the 71 sources its claims cite were checked for support.
Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention
Open accessAbstract
Cardiovascular diseases represent the leading cause of death in the world and are subject to limitations in prevention strategies despite the use of very effective drugs. The concept of residual risk (RR) is intrinsically related to that of global risk of which it represents a very significant percentage. In the cardiovascular field, the term RR refers to the probability of incurring a major cardiovascular event, despite adequate control of the risk factors present in the individual patient. A significant portion of the RR in the cardiovascular field results from the underestimation of additional risk factors not subjected to adequate intervention such as, for example, triglyceride levels in patients treated for the presence of hypertension and/or hypercholesterolemia. The control of the RR therefore appears as an essential condition for the effective reduction of the global risk profile and is based on an integrated intervention that combines all the different prevention strategies derived from the available evidence and capable of interacting on the basis of a strengthening reciprocal between lifestyle and pharmacological and nutraceutical intervention methods.
Overview
CoChat Summary
TL;DR
This paper is a narrative review of residual cardiovascular risk, arguing that LDL-C lowering alone leaves important risk unexplained and highlighting remnant cholesterol, monocyte/HDL ratio, and several lipoprotein ratios as additional markers. It summarizes prior studies suggesting these markers improve risk stratification and may identify patients with ongoing risk despite statin therapy.
Key findings
- Residual cardiovascular risk is defined here as the probability of a major cardiovascular event despite treatment according to standards of care, and the paper argues that classic risk calculators may underestimate risk in treated patients.
- Remnant cholesterol is presented as an independent risk marker: in non-fasting populations, RC values > 43 mg/dL were associated with a 2–3 times greater risk of ischemic heart disease than values < 15 mg/dL, and a 1 mmol/L (39 mg/dL) increase in RC was associated with a 2.8-fold increase in coronary heart disease risk.
- Monocyte/HDL ratio (MHR) is described as a marker of inflammation and cardiovascular risk; reported cut-offs included 12.1 for hemodynamically significant coronary stenosis, 30.1 for higher mortality/MACE risk in STEMI, and 17.5 for predicting 30-day mortality in stroke.
- Lipoprotein ratios were reported to outperform single lipids in predicting risk; the paper cites CT/HDL-C values ≥ 5.5 and LDL/HDL-C > 5 as associated with increased coronary event risk, and TG/HDL-C > 4 as a strong independent predictor of coronary artery disease and microvascular dysfunction.
Methods
- Narrative review article synthesizing prior epidemiological, clinical, and experimental studies on residual cardiovascular risk markers.
- No new sample was collected by the authors; instead, the paper summarizes cited studies, including examples such as 301 angiography patients, 440 STEMI patients, 1170 STEMI patients, 2312 type 2 diabetes patients undergoing angioplasty, and a Danish population cohort of over 90,000 individuals followed for 22 years.
- The main analysis is qualitative comparison of the prognostic value of remnant cholesterol, MHR, platelet/lymphocyte ratio, lipoprotein ratios, apoB, non-HDL cholesterol, and Lp(a) against conventional LDL-C-centered assessment.
Limitations
- Not stated in the paper.
- Evident from the text: this is a review, not an original study, so its conclusions depend on the quality and heterogeneity of the cited literature rather than a single unified dataset.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
23 Valid · 5 Not valid · 41 Not checked · 12 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Traditional risk factors alone cannot fully explain the high impact of coronary events in effectively treated patients; in fact, the classic calculators for estimating cardiovascular risk that only consider conventional risk factors, such as the Framingham risk score, could underestimate the risk in this particular population [8].”
§ Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention > 2. Residual Cardiovascular Risk: New Evidence
What the sources say
- Partly supportedcites [8] Piepoli, 2016, 2016 European Guidelines on cardiovascular disease prevention in clinical practice, Eur. Heart J. sourceExperimental — accuracy not yet measured
Section 2.3.6 (p. 16) says conventional risk factors in risk charts may need additional modifiers, and section 2.1 (p. 7) reports residual cardiovascular risk during treatment. Neither passage establishes that traditional factors fail to explain coronary events specifically in effectively treated patients, or that Framingham underestimates risk in that population. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, when it comes to antioxidative activity and cholesterol efflux capacity, the deficiency observed in HDL’s normal function falls short of complete dysfunction [9].”
§ Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention > 2. Residual Cardiovascular Risk: New Evidence > 2.1. Dysfunctional HDL
What the sources say
- Supportedcites [9] Rosenson, 2016, Dysfunctional HDL and atherosclerotic cardiovascular disease, Nat. Rev. Cardiol. source
The ‘Concept of dysfunctional HDL’ section explicitly distinguishes a deficiency in normal HDL function from complete dysfunction for antioxidative activity and cholesterol efflux capacity. This directly supports the citing sentence. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, there are instances where HDL’s ability to deliver cholesterol esters via SCARB1 may be reduced, indicating only a partial loss of function.”
§ Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention > 2. Residual Cardiovascular Risk: New Evidence > 2.1. Dysfunctional HDL
What the sources say
- Supportedcites [9] Rosenson, 2016, Dysfunctional HDL and atherosclerotic cardiovascular disease, Nat. Rev. Cardiol. source
The “Concept of dysfunctional HDL” section directly states that HDL’s capacity to deliver cholesteryl esters by SCARB1 might be attenuated, demonstrating only a partial loss of function. The claim preserves both the possibility and the qualification in the source. (LLM, conf=0.95)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In fact, the statistical analysis showed that the RC values were independently associated with the ISR, and in particular, the baseline value of 0.505 mmol/L (19.5 mg/dL was identified as the optimal cut-off to predict this complication of coronary angioplasty [25].”
§ Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention > 3. Remnants Cholesterol
What the sources say
- Supportedcites [25] Qin, 2019, Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: A single-center observational cohort study, Cardiovasc. Diabetol. source
The Results (Baseline clinical and angiographic characteristics, Total population) state that, after adjustment in a multivariate Cox model, RLP-C was an independent predictor associated with ISR in patients with type 2 diabetes after PCI. This supports the quoted claim about remnant cholesterol and in-stent restenosis. (LLM, conf=0.93)
plainstates an associationn = 2,312- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Elevated Lp(a) levels have been associated with increased risks of coronary and cerebrovascular events, peripheral artery disease, heart failure, and atrial fibrillation [12].”
§ Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention > 2. Residual Cardiovascular Risk: New Evidence > 2.2. Lipoprotein (a) The Lp(a) particle resembles LDL in its cholesterol-rich composition and consists of apolipoprotein B covalently linked to apolipoprotein(a) [apo(a)]. Its connection to cardiovascular risk, atherosclerosis, and coronary artery disease has gained attention [10,11]. Elevated Lp(a) levels have been associated with increased risks of coronary and cerebrovascular events, peripheral artery disease, heart failure, and atrial fibrillation [12]. Studies, such as the Copenhagen City Heart Study involving 9330 individuals, indicate a progressive rise in myocardial infarction risk over a decade with increasing Lp(a) levels [13]. Notably, Lp(a) is associated with premature atherosclerosis and juvenile acute coronary syndrome (ACS), with younger individuals exhibiting a higher probability of ACS with increasing Lp(a) levels compared to middle-aged individuals. Recent categorization of Lp(a) levels suggests that levels below 30 mg/dL (75 nmol/L) indicate a lower cardiovascular risk, while levels between 30 and 50 mg/dL (75–125 nmol/L) represent a “gray zone” in terms of risk [12]. Controversy exists regarding the effects of statins on Lp(a) levels, with some studies suggesting an increase in statin-treated patients, particularly those with small apo(a) phenotypes. However, statins are crucial for patients with elevated Lp(a) levels due to their efficacy in intense LDL reduction [12]. Niacin lowers ApoB-containing particle levels through various mechanisms, and the potential impact of PCSK9 inhibitors on Lp(a) levels alongside niacin therapy has been proposed. Clinical trials have shown a median reduction in Lp(a) percentage with PCSK9 inhibitors, but this reduction does not translate into a decrease in cardiovascular events [14,15]. Combination therapy with niacin and statins poses an increased risk of adverse effects. ASOs targeting ApoB mRNA, such as mipomersen, can reduce both LDL cholesterol and Lp(a) levels, but their side effects limit their use [16]. CETP inhibitors, like anacetrapib, have shown promise in reducing Lp(a) levels, primarily through diminishing apo(a) production [17]. Emerging therapies targeting apo(a) mRNA, such as pelacarsen and olpasiran, demonstrate significant reductions in Lp(a) levels without notable safety concerns. Clinical trials of these therapies show promising results in reducing cardiovascular events. A phase 1 trial of muvalaplin, a novel orally administered drug targeting the non-covalent interaction between apo(a) and apoB, has been recently completed [18]. During ESC Congress 2023, results demonstrated dose-dependent increases in plasma concentrations with muvalaplin, along with decreased Lp(a) levels and no associated safety or tolerability issues.
What the sources say
- Partly supportedcites [12] Kamstrup, 2016, Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population, JACC Heart sourceExperimental — accuracy not yet measured
The Results report increasing heart-failure risk with higher lipoprotein(a) levels, and the Discussion describes an association with coronary heart disease. The paper does not establish the claimed associations with cerebrovascular events, peripheral artery disease, or atrial fibrillation. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
41 more claims · 11 with their cited sources checked
Create a free account to see all 81 claims and to verify the 11 references still open.
- It may state two separate claims as one. 26
- Probably not a substantial claim. 14
Citations
Cites
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449 · cited 2×
“Vallejo-Vaz, A.J. et al. observed that RC values, in patients suffering from ischemic heart disease, were significantly correlated with the development of major adverse cardiovascular events (MACEs) [11].”
BackgroundManninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329 · cited 1×
“The latter seems to have a validity similar to that of the TC/HDL-C ratio, since approximately two thirds of plasma choles-J terol is found in LDL, and consequently, total cholesterol and LDL cholesterol are closely correlated [35].”
BackgroundRemnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115 · cited 2×
“Furthermore, it has been shown that individuals with non-fasting CR values > 43 mg/dL had a 2–3 times greater risk of ischemic heart disease compared to subjects with values 15 mg/dL [22,23].”
BackgroundInfluentialGlobal epidemiology of dyslipidaemias
Pirillo, A., Casula, M., Olmastroni, E., Norata, G. D., & Catapano, A. L. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00541-4 · Cited by 882 · cited 1×
“The primary characteristic of dyslipidemia is the rise in LDL cholesterol levels, which is closely linked to an elevated risk of cardiovascular disease, particularly atherosclerotic cardiovascular disease (ASCVD) [3,4].”
BackgroundDysfunctional HDL and atherosclerotic cardiovascular disease
Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.124 · Cited by 822
Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention
Munoz (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6269 · Cited by 760
Cited by
Wang, F., & Li, Q. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1603907 · Cited by 4
“RC is calculated by subtracting high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) from total cholesterol (TC) and re fl ects the accumulation of triglyceride-rich lipoproteins, such as very-low-density lipoproteins and chylomicron remnants (23 – 25).”
Impact of posterior occlusal contact loss on cardiovascular disease using a Japanese claims database
Miyano, T., Tamada, Y., Kusama, T., Osaka, K., & Takeuchi, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-01846-x · Cited by 5
Sucato, V., Fazio, L. D., Madaudo, C., Vadalà, G., D’Agostino, A., Evola, S., Novo, G., Corrado, E., & Galassi, A. R. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11050146 · Cited by 5
“Several trials demonstrated that in almost all dyslipidemic patients who undergo intensive lipid-lowering treatment (also, those who reach the “target values”), a significant residual cardiovascular risk persists [11].”
BackgroundSelf-citationJiang, Z., Zhao, K., Sun, M., Sun, J. G., & Pan, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1461613 · Cited by 2
Sharma, P., Rakshit, G., Banerjee, S., & Sharma, N. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178254 · Cited by 2
Metadata
- Authors
- Sucato, V., Comparato, F., Ortello, A., Galassi, A. R., & Novo, G.
- Affiliations
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
- Corresponding author
- Sucato, Vincenzo
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2024-04-26
- Volume
- 14
- Issue
- 5
- Pages
- 460
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC11122230
- OpenAlex
- W4395676315
- Cited by
- 12
- References
- 48
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 2
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS UniPA (University of Palermo) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Keywords
- residual cardiovascular risk, remnant cholesterol, monocyte/HDL ratio, lipoprotein ratios, cardiovascular disease prevention, triglycerides, hypercholesterolemia, hypertension, personalized prevention, lifestyle intervention, nutraceuticals, pharmacological interventions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention. https://app.cochat.ai/papers/10.3390/jpm14050460
- The paper
- Sucato, V., Comparato, F., Ortello, A., Galassi, A. R., & Novo, G. (2024). Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention. Journal of Personalized Medicine. https://doi.org/10.3390/jpm14050460
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
